標(biāo)題: Titlebook: Handbook of Biologics for Rheumatological Disorders; Neeraj Jain,Lalit Duggal Book 2022 The Editor(s) (if applicable) and The Author(s), u [打印本頁] 作者: Herbaceous 時(shí)間: 2025-3-21 17:44
書目名稱Handbook of Biologics for Rheumatological Disorders影響因子(影響力)
書目名稱Handbook of Biologics for Rheumatological Disorders影響因子(影響力)學(xué)科排名
書目名稱Handbook of Biologics for Rheumatological Disorders網(wǎng)絡(luò)公開度
書目名稱Handbook of Biologics for Rheumatological Disorders網(wǎng)絡(luò)公開度學(xué)科排名
書目名稱Handbook of Biologics for Rheumatological Disorders被引頻次
書目名稱Handbook of Biologics for Rheumatological Disorders被引頻次學(xué)科排名
書目名稱Handbook of Biologics for Rheumatological Disorders年度引用
書目名稱Handbook of Biologics for Rheumatological Disorders年度引用學(xué)科排名
書目名稱Handbook of Biologics for Rheumatological Disorders讀者反饋
書目名稱Handbook of Biologics for Rheumatological Disorders讀者反饋學(xué)科排名
作者: chance 時(shí)間: 2025-3-21 21:11
Biologics in Rheumatoid Arthritis,ombination with hydroxychloroquine (200?mg/day), oral methotrexate (15?mg/week) and leflunomide (10?mg/day). Her physician hikes her disease modifying anti rheumatic drug (DMARD) doses to hydroxychloroquine (400?mg/day), subcutaneous methotrexate (25?mg/week) and leflunomide (20?mg/day) and adds low作者: Flu表流動(dòng) 時(shí)間: 2025-3-22 00:56
Biologics in Spondyloarthritis,vent. They are the single most effective treatment option by a distance for axial SpA (axSpA), where the science of rheumatology had found itself limited until a couple of decades back. Apart from their numero uno position in the management of Ankylosing Spondylitis (AS), they are also very effectiv作者: Trypsin 時(shí)間: 2025-3-22 07:45
Biologics in Psoriatic Arthritis, enthesitis, dactylitis, skin and nail disease [1, 2]. Treatment of PsA has witnessed a sea change over the past two decades. Extra-articular manifestations including uveitis and inflammatory bowel disease, and comorbidities like obesity, metabolic disease and depression play critical roles in treat作者: 頑固 時(shí)間: 2025-3-22 10:35
Biologics in Gout,t. For the vast majority of patients, such therapy is sufficient to “cure” gout. Pegloticase, a biologic urate-lowering drug is in consideration when conventional urate-lowering treatments (ULTs) are ineffective due to inefficacy, intolerance, or contraindications. Similarly, low-dose prednisolone, 作者: MUTED 時(shí)間: 2025-3-22 14:23
Biologics in Systemic Lupus Erythematosus (SLE),e is characterized by periods of flare and remission, leading to accrual of damage in multiple organ systems, which is contributed by ongoing disease activity and treatment-related toxicities. More effective but less toxic therapies are unmet needs for the management of SLE. A number of novel agents作者: DEVIL 時(shí)間: 2025-3-22 18:24 作者: Incompetent 時(shí)間: 2025-3-22 21:33 作者: 北極熊 時(shí)間: 2025-3-23 03:54
Biologics in Idiopathic Inflammatory Myopathies,Treatable subtype of IIM include (juvenile) dermatomyositis ((j)DM), antisynthetase syndrome (ASS), immune-mediated necrotizing myopathy (IMNM) and overlap/non-specific myositis [OM/NSM, formerly called polymyositis (PM)]. Treatment of Idiopathic inflammatory myositis (IIMs), is not only long and of作者: 使增至最大 時(shí)間: 2025-3-23 08:47 作者: 東西 時(shí)間: 2025-3-23 11:54
,Biologics in Behcet’s syndrome,s including the mucosal and epithelial barriers of the orogenital apparatus, blood vessels, eyes as well as relatively devastating effects in the brainstem and pulmonary vasculature. The mucocutaneous manifestations of oral and genital ulcers resemble autoinflammatory disorders and are associated wi作者: CURL 時(shí)間: 2025-3-23 14:58 作者: 同音 時(shí)間: 2025-3-23 20:37
Biologics in Interstitial Lung Diseases in Rheumatological Disorders,oimmune rheumatic diseases (SARDs). Biologic disease modifying anti-rheumatic drugs (bDMARDs) are commonly used in the treatment of various SARDs. Because of the inflammatory nature of ILD, bDMARDs have also been tried in its treatment. No formal guidelines exist on the use of bDMARDs in the treatme作者: 貿(mào)易 時(shí)間: 2025-3-23 22:31
Biologics in Osteoporosis, With increasing longevity the burden of this condition worldwide is exponentially rising. Our increasing understanding of bone biology with insights into physiology, function and signalling network between osteoclasts, osteoblasts and osteocytes has paved the way for identification of newer therape作者: 鉆孔 時(shí)間: 2025-3-24 02:41 作者: itinerary 時(shí)間: 2025-3-24 10:30
Biologics in Juvenile Idiopathic Arthritis,y, synthetic disease modifying agents have been used with varying degrees of clinical improvement. The development of biologics has revolutionized the treatment of JIA. These therapies are often more efficacious and have proven to be of significant benefit in children with refractory arthritis. Thes作者: 調(diào)整校對(duì) 時(shí)間: 2025-3-24 10:41
Biologics in Pediatric Connective Tissue Disorders,n priority from saving lives to providing optimum quality of life, especially for children with these chronic diseases. Biologics, particularly Rituximab has been a useful addition in the management of refractory SLE, JDM, and ANCA vasculitis. Although trials of Belimumab in SLE and Infliximab in Ka作者: 證實(shí) 時(shí)間: 2025-3-24 14:49 作者: intimate 時(shí)間: 2025-3-24 19:14 作者: 同來核對(duì) 時(shí)間: 2025-3-25 01:50 作者: 寡頭政治 時(shí)間: 2025-3-25 03:57
https://doi.org/10.1057/9780230206618ombination with hydroxychloroquine (200?mg/day), oral methotrexate (15?mg/week) and leflunomide (10?mg/day). Her physician hikes her disease modifying anti rheumatic drug (DMARD) doses to hydroxychloroquine (400?mg/day), subcutaneous methotrexate (25?mg/week) and leflunomide (20?mg/day) and adds low作者: 能夠支付 時(shí)間: 2025-3-25 09:50 作者: URN 時(shí)間: 2025-3-25 15:23 作者: 劇毒 時(shí)間: 2025-3-25 17:18
https://doi.org/10.1007/978-3-319-04120-9t. For the vast majority of patients, such therapy is sufficient to “cure” gout. Pegloticase, a biologic urate-lowering drug is in consideration when conventional urate-lowering treatments (ULTs) are ineffective due to inefficacy, intolerance, or contraindications. Similarly, low-dose prednisolone, 作者: 險(xiǎn)代理人 時(shí)間: 2025-3-25 21:56
https://doi.org/10.1007/978-94-015-1065-3e is characterized by periods of flare and remission, leading to accrual of damage in multiple organ systems, which is contributed by ongoing disease activity and treatment-related toxicities. More effective but less toxic therapies are unmet needs for the management of SLE. A number of novel agents作者: 大包裹 時(shí)間: 2025-3-26 03:53
,Lichtenberg’s Philosophy of Education,ogic therapy. There are focal CD4+ T cell predominant inflammatory infiltrates within salivary glands and other organs, evidence of raised pro-inflammatory cytokines, including IFN-gamma, IL-17 and IL-21 and prominent B-cell lymphoproliferation with a 15 fold increased lifetime risk of B-cell lympho作者: 無能力 時(shí)間: 2025-3-26 04:27 作者: 弄皺 時(shí)間: 2025-3-26 09:14 作者: 愚笨 時(shí)間: 2025-3-26 14:19
Chartism: The Working-class Threat,o Granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA) [1]. The management of AAV has seen a turn in the last few decades with a change in status from a fatal disease to a manageable chronic disease [2].作者: 香料 時(shí)間: 2025-3-26 18:56 作者: Indicative 時(shí)間: 2025-3-27 00:15
of paucity of biomarkers, some preliminary tools for assessing the disease like ITAS2010 and ITAS A (CRP) are being made available in day-to-day clinical practice. Hopefully, these ongoing advancements will make “treat to target” in TA a reality, sooner than later.作者: notice 時(shí)間: 2025-3-27 03:03 作者: Hyaluronic-Acid 時(shí)間: 2025-3-27 08:44 作者: 容易做 時(shí)間: 2025-3-27 13:01 作者: 暴行 時(shí)間: 2025-3-27 14:27
Ji?í Hrabák,Vít Jan?ák,Veronika Eretováy, synthetic disease modifying agents have been used with varying degrees of clinical improvement. The development of biologics has revolutionized the treatment of JIA. These therapies are often more efficacious and have proven to be of significant benefit in children with refractory arthritis. Thes作者: 蟄伏 時(shí)間: 2025-3-27 18:52
Analysis Technics of Seismic Signals,n priority from saving lives to providing optimum quality of life, especially for children with these chronic diseases. Biologics, particularly Rituximab has been a useful addition in the management of refractory SLE, JDM, and ANCA vasculitis. Although trials of Belimumab in SLE and Infliximab in Ka作者: 獨(dú)特性 時(shí)間: 2025-3-28 00:59 作者: IRS 時(shí)間: 2025-3-28 02:28
Three Frames of Modern Politicsthis also leads to a degree of immunosuppression which increases the patient’s susceptibility to infection..Apart from the infectious complications related to treatment with biological agents, potent reactivation of ., Hepatitis B, C, HIV infections can be associated with significant morbidity and m作者: Hyperplasia 時(shí)間: 2025-3-28 07:01
https://doi.org/10.1007/978-3-030-81082-5ese physicians would be least interested in the history of the discovery of these drugs that are nothing short of ‘miracles’ if there ever was one. Yet the story of the discovery of the biologicals is like a highly engrossing novel with excitements, despair, thrills and ecstasy with an intense ending.作者: 憤慨一下 時(shí)間: 2025-3-28 10:43 作者: Diaphragm 時(shí)間: 2025-3-28 15:43
,Lichtenberg’s Philosophy of Education,ma compared to the normal population. Despite this biologic therapy has been generally disappointing to date. Some studies have shown positive serological signals but with poor clinical correlation suggesting that patient selection or disease duration may be a factor determining response.作者: 洞察力 時(shí)間: 2025-3-28 20:30
Thermodynamics and the Temporal Asymmetriesnt of ILD. Available literature shows conflicting results about the efficacy and safety of bDMARDs in ILD. Moreover, many of the commonly used bDMARDs have been shown to induce or worsen pre-existing ILD. We discuss in this chapter the current status of bDMARDs in the treatment of ILD.作者: 蔓藤圖飾 時(shí)間: 2025-3-29 01:59 作者: ineluctable 時(shí)間: 2025-3-29 04:58
,A Historical Introduction to the Biological Response Modifier Drugs: The ‘Biologicals’,ese physicians would be least interested in the history of the discovery of these drugs that are nothing short of ‘miracles’ if there ever was one. Yet the story of the discovery of the biologicals is like a highly engrossing novel with excitements, despair, thrills and ecstasy with an intense ending.作者: 肥料 時(shí)間: 2025-3-29 10:33
Biologics in Rheumatoid Arthritis, dose prednisolone 5?mg/day. Two months later she reports to him with partial relief: CDAI of 18. She is Cushingoid and wants to stop her corticosteroids. He advises her to take biologics and refers her to a rheumatologist.作者: 倔強(qiáng)不能 時(shí)間: 2025-3-29 12:39
,Biologics in Sjogren’s Syndrome,ma compared to the normal population. Despite this biologic therapy has been generally disappointing to date. Some studies have shown positive serological signals but with poor clinical correlation suggesting that patient selection or disease duration may be a factor determining response.作者: 大都市 時(shí)間: 2025-3-29 17:00
Biologics in Interstitial Lung Diseases in Rheumatological Disorders,nt of ILD. Available literature shows conflicting results about the efficacy and safety of bDMARDs in ILD. Moreover, many of the commonly used bDMARDs have been shown to induce or worsen pre-existing ILD. We discuss in this chapter the current status of bDMARDs in the treatment of ILD.作者: endocardium 時(shí)間: 2025-3-29 20:12
Biologics in Pediatric Connective Tissue Disorders,wasaki disease have shown encouraging results, they still have not been widely accepted in clinical practice due to toxicity and cost concerns. With a better understanding of these rare diseases and ongoing clinical trials enrolling children with CTD, biologics may be the first-line drugs in near future.作者: 輕率看法 時(shí)間: 2025-3-30 01:39 作者: Platelet 時(shí)間: 2025-3-30 05:14
Biologics in Psoriatic Arthritis,tarium of patients with PsA. Significant responses in all the relevant clinical domains, coupled with the ability to inhibit progressive structural damage in the joints, have yielded bDMARDs a clear edge over the conventional (c) DMARDs in most patients with PsA.作者: meritorious 時(shí)間: 2025-3-30 10:32
Biologics in Spondyloarthritis,ted until a couple of decades back. Apart from their numero uno position in the management of Ankylosing Spondylitis (AS), they are also very effective for treating peripheral SpA (pSpA), as well as non-radiographic axSpA (nr-axSpA). The following text shall provide an overview of the various bDMARDs and their applications in SpA.作者: nocturia 時(shí)間: 2025-3-30 14:51 作者: 不規(guī)則的跳動(dòng) 時(shí)間: 2025-3-30 19:30
Biologics in Osteoporosis,into physiology, function and signalling network between osteoclasts, osteoblasts and osteocytes has paved the way for identification of newer therapeutic targets. This chapter provides an update on drug treatments for osteoporosis currently in use and those awaiting approval by regulatory authorities.作者: 散步 時(shí)間: 2025-3-30 21:24
Interviews with Hospital Presidents,f 80%. High resolution chest CT imaging (HRCT) shows mild interstitial lung disease (ILD) with visual read estimate of 5% fibrosis. Her clinical presentation prompts consideration for a biologic therapy.作者: OVERT 時(shí)間: 2025-3-31 03:11 作者: inventory 時(shí)間: 2025-3-31 05:11
Ji?í Hrabák,Vít Jan?ák,Veronika Eretová biologic agents. Anti- TNFα therapy is effective across several JIA subsets. Early intensive therapy in a certain subset like systemic JIA can alter the biology of the disease and improve long-term disease outcomes and damage.作者: 要求比…更好 時(shí)間: 2025-3-31 12:41
Three Frames of Modern Politicsrsally recommended and specific screening guidelines advocated. In addition, the presence of any serious active infection should deter the initiation or continuation of biologic therapy till the infection is resolved.作者: 努力趕上 時(shí)間: 2025-3-31 13:24
Biologics in Systemic Sclerosis,f 80%. High resolution chest CT imaging (HRCT) shows mild interstitial lung disease (ILD) with visual read estimate of 5% fibrosis. Her clinical presentation prompts consideration for a biologic therapy.作者: OUTRE 時(shí)間: 2025-3-31 18:48
Biologics in Osteoarthritis,t is also associated with increased mortality being associated with poor control of Diabetes and Heart disease. Osteoarthritis Research Society Internationale has labelled it as a “Serious disease” requiring urgent measures to tackle the disease.作者: 天賦 時(shí)間: 2025-4-1 00:10 作者: SENT 時(shí)間: 2025-4-1 04:25 作者: 寬宏大量 時(shí)間: 2025-4-1 06:01
Book 2022nts and expanded use of existing agents continues to be a highly active area of investigation among rheumatic diseases, with a multitude of innovative therapeutic strategies in various stages of development. Although the story of treatments continues rapidly, therapeutic research in some conditions
